MCC950‐Loaded M12‐Liposome Nanoparticles for Targeted Inhibition of NLRP3 Inflammasome in Sepsis‐Induced Muscle Atrophy

Key Points

• This research aims to investigate the effectiveness of MCC950-loaded M12-liposome nanoparticles in targeting the NLRP3 inflammasome in muscle atrophy due to sepsis.
• Developed MCC950-loaded M12-liposome nanoparticles for targeted delivery.
• Administered nanoparticles to skeletal muscle.
• Assessed inhibition of NLRP3 inflammasome activation and muscle atrophy.
• M12-liposome@MCC950 nanoparticles significantly inhibited NLRP3 inflammasome activity.
• Observed relief from muscle atrophy in sepsis models.
• Reduced systemic toxicity compared to traditional delivery methods.